Temozolomide has been used as a standard therapy for the treatment of newly diagnosed glioblastoma multiforme since 2005. To assess the effectiveness of temozolomide in routine clinical practice, we conducted an observational study at Maastricht University Medical Centre (MUMC). Data of patients receiving radiotherapy and temozolomide between January 2005 and January 2008 were retrieved from a clinical database (radiochemotherapy group), as were data of patients in a historical control group from the period before 2005 treated with radiotherapy only (radiotherapy group). The primary endpoint was overall survival. A total of 125 patients with GBM were selected to form the study cohort. Median survival benefit was 4 months: the median overall survival was 12 months (95% CI, 9.7–14.3) in the group with radiochemotherapy with temozolomide, versus 8 months (95% CI, 5.3–10.7) in the group with only radiotherapy. Progression-free survival was 7 months (95% CI, 5.5–8.5) in the radiochemotherapy group and 4 months (95% CI, 2.9-5.1) in the group with only radiotherapy. The two-year survival rate was 18% with radiochemotherapy with temozolomide against 4% with radiotherapy alone. Concomitant treatment with radiotherapy and temozolomide followed by adjuvant temozolomide resulted in grade III or IV haematological toxic effects in 9% of patients. The addition of temozolomide to radiotherapy in routine clinical practice for newly diagnosed glioblastoma resulted in a clinically meaningful survival benefit with minimal haematological toxicity, which confirms the experience of previous trials and justifies the continued use of temozolomide in routine clinical practice.
Introduction
Gliomas represent about half of all histologically verified primary CNS cancers among adults [1]. Glioblastoma multiforme (GBM), grade IV glioma, is the most frequent and most aggressive type of malignant brain tumour. The most characteristic features of GBM are necrosis and endothelial proliferation [2]. Despite the best available treatment, the clinical course is fatal, with a median survival of less than one year [3]. Factors that are prognostic for survival, apart from treatment modalities, are patient age, performance status and degree of surgical resection [1, 3‐13]. When a high grade glioma is suspected, maximal resection of the tumour is aimed for, on condition that neurological functions are spared. Such cytoreductive surgery is of limited value without adjuvant therapy. Until 2005, standard therapy consisted of surgical resection, followed by radiotherapy, which has been shown to prolong survival [14]. Unfortunately, the addition of various chemotherapeutics only resulted in marginal survival benefits [15, 16]. Therefore, chemotherapy was not part of standard therapy for GBM in Europe and was only administered in the context of clinical trials. This changed after the publication of an EORTC/NCIC study in 2005, in which Stupp et al. demonstrated improved survival in patients with a histological diagnosis of glioblastoma multiforme, when concomitant temozolomide followed by adjuvant temozolomide was added to the standard treatment [17]. Similar results were seen in a smaller phase II trial by Athanassiou et al [18]. Temozolomide is an oral alkylating agent, with a lower toxicity profile than most other chemotherapeutic agents [19]. It can easily cross the blood-brain barrier, so that cerebrospinal fluid levels can reach at least 20% of those observed in the plasma [20]. Since the publication of these studies, temozolomide has been widely adopted as the new standard of care for patients with newly diagnosed GBM.
The outcome of randomised controlled trials cannot be directly applied without considering differences in patient characteristics between the trial population and patient populations in routine clinical practice. The objective of the present study was to assess the effectiveness of temozolomide in addition to radiotherapy in patients with newly diagnosed GBM in routine clinical practice. For this purpose, we conducted an observational study at Maastricht University Medical Centre (MUMC) among patients receiving radiotherapy and temozolomide and a historical control group of patients who were treated with radiotherapy only.
Anzeige
Patients and methods
Study objectives
The primary endpoint in this study was overall survival (OS), defined as the time from the starting date of radiotherapy to the date of death. Secondary endpoints were progression-free survival (PFS), 2-year overall survival and toxicity. PFS was defined from the starting date of radiotherapy to the date of tumour progression or death. The exact date of death was acquired from a database held at the General Registry Office of the Dept. of Radiation Oncology (MAASTRO Clinic). The safety and tolerability of temozolomide were estimated in the radiotherapy plus temozolomide group by assessing the haematological and non-haematological toxicity data from medical records and routine blood examinations. Although the National Cancer Institute has updated its Common Toxicity Criteria into version 3.0 (2006), we used version 2.0 to ensure better comparability with previous trials.
Eligibility
Since 1991, the Neuro-Oncology Department of the MUMC has been entering data on all neuro-oncological patients who are discussed in its weekly neuro-oncology meetings into a database. For the present study, we added data on patients who had not been discussed in these neuro-oncology meetings, but who had been registered in a pathology database (PALGA) with a histological GBM diagnosis. This allowed us to identify all patients aged 18 to 70 years who had a newly diagnosed and histologically confirmed supratentorial GBM according to the World Health Organization classification and who had been referred to the MUMC between January 2000 and January 2008. Data of patients who received radiotherapy and temozolomide between January 2005 and January 2008 were collected from this database (radiochemotherapy group). Data of patients receiving radiotherapy only were retrieved from the database for the period before 2005 (radiotherapy group). The subtypes of GBM, namely giant cell and gliosarcoma, were included.
Patients with a secondary glioblastoma, based on a prior histopathological diagnosis of a lower grade astrocytoma, were excluded. In cases where the first histopathological diagnosis was glioblastoma, but the clinical history was longer than one year, the pathologist was asked to do further immunohistochemical examinations to confirm or exclude the diagnosis of primary glioblastoma. Patients with gliomatosis cerebri were excluded, as well as patients with prior chemotherapy.
Treatment
All patients had surgery before radiotherapy. The extent of the surgery was defined as biopsy, partial resection or macroscopically complete resection and was determined from the surgical report and postoperative imaging, if performed. In the radiochemotherapy group, patients received radiotherapy with concomitant temozolomide, followed by adjuvant temozolomide, whereas the reference group received radiotherapy only (same radiotherapy treatment scheme with 30 fractions of 2 Gy to total dose of 60 Gy as used in the EORTC study by Stupp et al. [17]). Chemotherapy consisted of temozolomide at a dose of 75 mg/m2 per day, seven days a week for 42 consecutive days during radiotherapy. After a break of four weeks, patients received six cycles of adjuvant temozolomide at a dose of 150 to 200 mg/m2, on days 1 through 5, every 28 days. Prophylactic co-trimoxazol against Pneumocystis carinii was given. Antiemetics, anticonvulsants and corticosteroids were prescribed if needed.
Anzeige
In case of disease progression, patients were assessed for their performance status and were offered ‘salvage therapy’, such as surgery, re-irradiation, second-line chemotherapy and/or supportive care.
Statistical analysis
Overall and progression-free survival curves were plotted using the method developed by Kaplan and Meier. The Cox proportional hazards model was used to adjust the hazard ratio for confounding and to improve the statistical efficiency. The prognostic factors tested were age, sex, WHO performance status and extent of surgery, since these have been reported in the literature as prognostic factors for survival outcome [1, 3‐13].
We corrected for age per decade rather than the binary categories above or below 50 years, to obtain a more accurate measure of this variable. P-values lower than 0.05 were considered to be statistically significant. Statistical analysis was performed using the Statistical Package for the Social Sciences 15.0 (SPSS, Inc., Chicago, IL).
Results
Patient characteristics
One hundred and twenty-five patients with GBM were selected to form the study cohort. Patient details are outlined in Table 1. Median age was 56 years. Male/female ratio was 1.55. The initial complaints were motor symptoms in 34% of the patients, headache in 45%, epileptic seizures in 33%, personality change in 12%, and speech disorder in 26%. The radiochemotherapy group consisted of 67 patients and the radiotherapy group of 58 patients. The median time from diagnosis to start of treatment was 5.9 weeks in the radiotherapy group and 3.9 weeks in the radiochemotherapy group. The baseline characteristics of the patients were not balanced as regards sex, extent of resection, corticosteroid use, giant cell or waiting time between diagnosis and the start of treatment.
Table 1
Patient characteristics
Characteristic
Radiotherapy (N = 58)
Radiochemotherapy (N = 67)
Age (year)
Median
56
57
Range
33–70
25–70
Sex––no. (%)
Male
29 (50)
47 (70)
Female
29 (50)
20 (30)
WHO performance status, no. (%)
0
23 (40)
25 (37)
1
24 (41)
30 (45)
2
8 (14)
11 (16)
3
3 (5)
1 (2)
Extent of surgery, no. (%)
Biopsy
33 (57)
30 (45)
Partial
11 (19)
12 (18)
Macroscopically complete resection
14 (24)
25 (37)
Time from diagnosis to treatment, wk
Median
5.9
3.9
Range
0.7-18
2-8.4
Corticosteroid therapy, no. (%)
Yes
39 (67)
46 (69)
No
5 (9)
20 (30)
Data missing
14 (24)
1 (2)
Subtype of glioblastoma, no. (%)
Giant cell
1 (2)
6 (9)
Treatment
Median received radiation dose was 60 Gy (range, 4–60 Gy). Ten patients (8%) did not complete the entire radiotherapy, reasons including disease progression and death. Among the 67 patients who started radiochemotherapy, 93% completed the concomitant phase with both radiotherapy and temozolomide. Of the 67 patients in the radiochemotherapy group, 75% started the adjuvant therapy with temozolomide after the 4-week break. Seventy percent of the radiochemotherapy group completed three cycles of temozolomide, and 40% had ultimately completed six cycles (see Table 2). The main reason for not completing concomitant and/or adjuvant temozolomide therapy in our study was disease progression, assessed by clinical deterioration and/or radiological assessment. Five patients (7.5%) in the radiochemotherapy group discontinued therapy because of haematological toxicity effects.
Table 2
Temozolomide compliance
Treatment episode
% Completed
Week 3 RT concomitant
100.0
Week 5 RT concomitant
97.0
Total concomitant period
92.5
Cycle 1
74.6
Cycle 2
73.1
Cycle 3
70.1
Cycle 4
44.7
Cycle 5
43.2
Cycle 6
40.3
Survival and progression
The follow-up ended on 8 July 2008. The unadjusted hazard ratio for death in the radiochemotherapy group compared to the radiotherapy group was 0.48 (95% CI, 0.32–0.72; P < 0.001). Multivariate analysis, including all considered covariates gave the same hazard ratio: 0.47 (95% CI, 0.29–0.73; P = 0.001). The Kaplan–Meier curve showed a median overall survival of 12 months (95% CI, 5.3 to 10.7) in the radiochemotherapy group, versus 8 months (95% CI, 9.7–14.3) in the group with radiotherapy only (Fig. 1 and Table 3). The estimated median survival benefit was therefore 4 months.
Fig. 1
Kaplan–Meier curves of overall survival: radiochemotherapy versus radiotherapy only. P value = 0.000. Censored: Still alive at end of study period 08-07-08
Table 3
Overall and progression-free survival
Variable
Radiotherapy (N = 47)
Radiochemotherapy (N = 66)
Value (95% CI)
Value (95% CI)
Median overall survival (months)
8.0 (5.3–10.7)
12.0 (9.7–14.3)
Overall survival (%)
At 6 months
57.4
78.8
At 12 months
23.4
46.8
At 24 months
4.3
18.2
Median progression-free survival (months)
4.0 (2.9–5.1)
7.0 (5.5–8.5)
Progression-free survival (%)
At 6 months
34.0
56.1
At 12 months
6.4
26.6
At 24 months
2.1
9.5
×
The unadjusted hazard ratio for PFS of radiochemotherapy compared to the radiotherapy was 0.58 (95% CI, 0.39–0.85; P = 0.006). The adjusted hazard ratio, corrected for all considered factors, was 0.59 (95% CI, 0.38–0.91; P = 0.016). The median progression-free survival was 7 months (95% CI, 5.5–8.5) with radiochemotherapy and 4 months (95% CI, 2.9–5.1) with only radiotherapy (Fig. 2, Table 3). The two-year survival rate was 18% in the radiochemotherapy group and 4% in the group with only radiotherapy.
Fig. 2
Kaplan–Meier curves of progression-free survival: radiochemotherapy versus radiotherapy only. P-value = 0.003. Censored: Still alive at end of study period 08-07-08
×
The waiting time (medians 5.9 for radiotherapy and 3.9 weeks for radiochemotherapy) was also added to the Cox Regression model. The adjusted hazard ratio for death of radiotherapy plus temozolomide compared to radiotherapy alone, then became 0.42 (95% CI, 0.24–0.73; P = 0.002). This change of the HR was caused by a clear positive association between waiting time and survival in the radiotherapy group as is shown in Fig. 3. This association is probably due to patient selection. In the radiochemotherapy period (2005–2008), there was a weak inverse association.
Fig. 3
Correlation between waiting time and survival in radiotherapy and radiochemotherapy groups
×
Anzeige
Subgroup analysis
Survival was analysed according to the prognostic factors. Radiochemotherapy was associated with a significant improvement in median overall survival in nearly all subgroups of patients, with the exception of the relatively large subgroup of patients who underwent biopsy only and the patients with a WHO performance status 1 (whereas those with the poorer performance status WHO 2 and 3 did show a significant improvement in median survival).
Comparison with EORTC/NCIC trial
To achieve the best possible comparison of the effect of this new treatment in routine clinical practice and in the EORTC/NCIC trial, we calculated what the effect of the treatment in our setting would have been for the patients of the EORTC/NCIC trial. To this end, we entered the mean patient characteristics of their trial population (Table 4) into our Cox regression model. The survival curve in Fig. 4 shows the effect of treatment on the survival of an average patient in the EORTC trial. This patient would be expected to survive for 10.0 months with radiotherapy and 14.2 months when temozolomide was added to the treatment. An average patient in our routine clinical practice cohort survived 9.0 months with radiotherapy and 12.9 months with radiochemotherapy (Fig. 5).
Table 4
Patient characteristics––comparison with EORTC/NCIC trial
Characteristic
Present study
Stupp et al.
RT
RT + TMZ
RT
RT + TMZ
Age (year)
Median
56
57
57
56
Sex (%)
Male
50
70
61
64
Female
50
30
39
36
WHO performance status (%)
0
40
37
38
39
1
41
45
49
47
2
14
16
12
13
3
5
2
0
0
Extent of surgery (%)
Biopsy
57
45
16
17
Partial
19
18
45
44
Macroscopically complete resection
24
37
40
39
Time from diagnosis to treatment––wk
Median
5.9
3.9
5.0
5.0
Corticosteroid therapy (%)
Yes
67
69
75
67
No
9
30
24
33
Data missing
24
2
<1
0
Subtype of glioblastoma (%)
Giant cell
2
9
?
?
Fig. 4
Survival curve of an average patient of the EORTC/NCIC trial
Fig. 5
Survival curve of an average patient of selected patients from clinical practice
×
×
Toxicity
Detailed toxicity data were not recorded for the radiotherapy group in the neurology treatment charts, whereas temozolomide-related haematotoxicity was recorded for each patient in the radiochemotherapy group. Six patients (9%) had any type of grade III or IV haematological toxic effect. In five of these cases chemotherapy was discontinued. Anti-epileptic drugs were given to 41% of patients in the radiotherapy group and 47% of patients in the radiochemotherapy group. Only 5% received the non-enzyme inducing valproic acid.
Treatment after disease progression
At the moment of disease progression, four patients in both treatment groups underwent a second surgery, seven patients were re-irradiated, 16 patients received additional cycles of temozolomide and four patients received second-line chemotherapy other than temozolomide. In total, 17% of patients in the radiochemotherapy group and 18% of patients in the radiotherapy group received salvage chemotherapy (see Table 5). Salvage chemotherapy consisted of additional cycles of temozolomide in 67% of patients in the radiochemotherapy group and 100% of patients in the radiotherapy group.
Table 5
Salvage treatment
Type of treatment
Radiotherapy (N = 47)
Radiochemotherapy (N = 66)
Second surgery, no. (%)
0 (0)
4 (6)
Re-irradiation, no. (%)
1 (2)
6 (9)
Chemotherapy, no. (%)
8 (17)
12 (18)
Temozolomide
8 (17)
8 (12)
Other than temozolomide
0 (0)
4 (6)
Anzeige
Discussion
Since the publication of randomised trials in which patients with newly diagnosed glioblastoma multiforme (GBM) showed a prolonged survival when treated with both radiotherapy and temozolomide, this chemotherapeutic agent has been implemented as the standard therapy. To verify the value of this established treatment with temozolomide in routine clinical practice, we conducted an observational study at the Maastricht University Medical Centre, comparing survival in a cohort of patients receiving radiochemotherapy with that in a historical control group receiving radiotherapy only. Our study showed that radiochemotherapy is indeed also effective in routine clinical practice, although the effectiveness is somewhat different from that in the published trials.
We found a median overall survival of 12.0 months in the group with radiochemotherapy and 8.0 months in the group with radiotherapy only. The median survival benefit in the present study was thus 4 months, which is lower than the 5.7 months benefit found by Athanassiou et al. but higher than the 2.5 months median survival benefit found by Stupp et al. (Table 6). [17, 18] In the study by Athanassiou et al. the dose of temozolomide during the concomitant phase was the same, but temozolomide was given every two instead of four weeks during the adjuvant phase. It remains unclear whether that is an explanation for the higher survival benefit in their study.
Table 6
Overall and progression-free survival––comparison with trials
Variable
Radiotherapy
Radiochemotherapy
Median (95% CI)
Median (95% CI)
Overall survival (months)
Present study
8.0 (5.5–10.5)
12.0 (9.7–14.3)
Stupp et al.
12.1 (11.2–13.0)
14.6 (13.2–16.8)
Athanassiou et al.
7.7 (5.3–9.2)
13.4 (9.6–17.1)
Progression-free survival (months)
Present study
4.0 (2.9–5.1)
7.0 (5.5–8.5)
Stupp et al.
5.0 (4.2–5.5)
6.9 (5.8–8.2)
Athanassiou et al.
5.2 (4.0–7.4)
10.8 (8.1–14.7)
In our study, 40% of all patients in the radiochemotherapy group completed the concomitant and total adjuvant treatments, which was slightly higher than the 36.6% in the study by Stupp et al. while 61.4% of the patients in the trial by Athanassiou et al. completed six cycles of temozolomide. The difference in compliance between the present study and the phase III trial by Stupp et al. can only partially explain the larger median survival benefit in our study.
The decrease in waiting time with median times of 5.9 until 2005 and 3.9 in recent years is the consequence of a more time-efficient approach to patients with GBM introduced in recent years. It has been reported that a delay until the first fraction of radiotherapy after surgery or after first consultation in the radiotherapy department results in a clinically significant reduction of survival for patients with glioblastoma [21‐24]. We investigated the correlation between waiting time and survival and found a positive association in the radiotherapy group, which seems to be responsible for the stronger therapeutic effect (lower hazard ratio) after correction for waiting time. This association is probably caused by selection: patients assessed as ‘better’ in terms of performance status had to wait longer for treatment. Recently Blumenthal et al. also showed that delaying initiation of radiotherapy did not show reduction in survival, but a superior outcome instead [25]. These comparable results may be based on the same kind of patient selection for early treatment as was mentioned before. The difference in waiting time between the two cohorts could not explain the larger survival benefit in the present study compared to the EORTC/NCIC trial (median waiting time being 5 weeks in both groups).
Anzeige
The fact that the median overall survival was shorter in both groups in the present study than in the EORTC/NCIC trial can at least partly be explained by a larger number of patients being surgically treated with biopsy only. In our study, 57% and 45% of the radiotherapy and radiochemotherapy groups, respectively, had a biopsy only, versus 16% and 17% in the EORTC/NCIC trial. Most studies have shown a significant survival advantage for patients undergoing a more extensive degree of resection [3, 5, 10, 12, 13]. Also one has to keep in mind that both our study and EORTC/NCIC trial did not show a clear survival advantage in the subgroup with patients undergoing biopsy [17].
Although we have corrected for the possible confounding factors, the slightly worse results in our MUMC cohort can also be the consequence of the well-known phenomenon of selection bias from patient selection for clinical trials.
Since a primary goal of therapy for patients with GBM is improvement or maintenance of quality of life, delaying disease progression by extending the progression-free survival is very important. The present study demonstrated that the addition of temozolomide to radiotherapy achieved a prolongation of the median progression-free survival from 4 months in the radiotherapy group to 7 months in the radiochemotherapy group (Table 6).
Survival from progression, that is, the difference between OS and PFS, was shorter in our study (4.0 and 5.0 months in the radiotherapy and radiochemotherapy groups, respectively) than in the EORTC/NCIC trial (7.1 and 7.7 months). This may be caused by less salvage treatment. In our study, only 17% of the radiotherapy group and 18% of the radiochemotherapy group received salvage chemotherapy, whereas in the EORTC/NCIC trial, 72% and 58%, respectively, received salvage chemotherapy after progression. In the EORTC/NCIC trial, 23% of patients in both treatment groups underwent repeat surgery, compared to only 4% in our study. Re-irradiation was given to 6% of patients in the present study (3% before 2005 and 9% since 2005). The number of patients receiving re-irradiation in the EORTC/NCIC trial was not reported [17].
Apart from biopsy and waiting time, reported patient characteristics of the randomised EORTC trial and our study were quite similar (Table 4). By estimating the treatment effect of the EORTC/NCIC trial population in our setting from our Cox regression model (Fig. 4), we showed that a quite similar survival benefit would have been accomplished as what was achieved in our study population (4.2 instead of 3.9 months) and a higher survival of 10 months with radiotherapy and 14.2 months with radiochemotherapy.
Among the 125 cases of glioblastoma multiforme included in this study, only seven patients (5.6%) had giant cell glioblastoma multiforme. Normally, giant cell GBM (GC-GBM) constitutes approximately 5% of the cases of glioblastoma multiforme, and GC-GBM is recognised as a distinct clinicopathologic entity in the WHO 2007 classification [2, 26]. The difference in the prevalence of the giant cell subtype between the two groups in our study (Table 1) is remarkable: one patient in the radiotherapy group and six in the radiochemotherapy group. This might be a coincidence but it is more probable due to a change in pathological analysis. Patients with giant cell GBM were on average 16.5 years younger than those with non giant cell GBM and macroscopically complete resection was possible in 71% patients versus 29% in non giant cell, probably contributing to a better survival [27]. Unfortunately, the Stupp trial did not mention the number of patients with giant cell subtype.
Our results demonstrate that temozolomide combined with radiotherapy is an effective chemotherapeutic agent for patients with primary glioblastoma multiforme in clinical practice.
Open Access
This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Open AccessThis is an open access article distributed under the terms of the Creative Commons Attribution Noncommercial License (https://creativecommons.org/licenses/by-nc/2.0), which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
Mit e.Med Neurologie & Psychiatrie erhalten Sie Zugang zu CME-Fortbildungen der Fachgebiete, den Premium-Inhalten der dazugehörigen Fachzeitschriften, inklusive einer gedruckten Zeitschrift Ihrer Wahl.
Mit e.Med Neurologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes, den Premium-Inhalten der neurologischen Fachzeitschriften, inklusive einer gedruckten Neurologie-Zeitschrift Ihrer Wahl.
Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.
Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.
Update Neurologie
Bestellen Sie unseren Fach-Newsletterund bleiben Sie gut informiert.
